Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2015 · 10-Q
Revenue$1.92K$1.92K−88.3% vs Q2 2014 Net Income-$557.72K-$557.72KN/M vs Q2 2014 EPS Diluted-$0.01-$0.01N/M vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$184,986N/M Margins · derivedGross margin30.3%−33.7 pt vs Q2 2014
Operating margin-25712.7%−20680.7 pt vs Q2 2014
Net margin-29048.1%−27813.9 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 19, 2015 · 50 d after period end